Overall verdict
Sell
2.7/10
1-year performance
—
Score breakdown
Strongest: Growth 10.0/10. Weakest: Shareholder return 0.0/10.
IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC). Its pipeline products includes IMP1734, a next-generation poly (ADP-ribose) polymerase (PARP)1 selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for the treatment of advanced solid tumors ;
IMP9064, an ataxia telangiectasia and Rad3-related kinase selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for advanced solid tumors ; IMP1707, a central nervous system penetrant, PARP1 selective inhibitor, which is in Phase I clinical trial for homologous recombination repair tumors ; and IMP7068, and advanced WEE1 inhibitor, which is in Phase I/II clinical trial for advanced solid tumors. The company also develops IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, which are in preclinical stage. The company was founded in 2009 and is based in Shanghai, China.
Sector
Health Care
Industry
Biotechnology
Primary listing
Hkex
China
CEO
Sui-Xiong Cai
Founded
2009
Employees
89
Revenue / employee
429 958 CNY
Next earnings
December 1, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
—
52-week low
—
1-year performance
—
Year-to-date performance
—
Position in the 52-week range
—
Gross margin 87.2%, the company loses 213.6% of its revenue, ROIC -60.5%, ROE -13630.8%.
Net margin
-213.59%
Negative
Sector -212.83%|S&P 13.35%
Gross margin
87.18%
Exceptional
Return on equity (ROE)
-13630.80%
Negative
Sector -55.30%|S&P 16.98%
Return on invested capital (ROIC)
-60.52%
Negative
Free cash flow margin (FCF)
-82.05%
Negative
Revenue to net income
Growth
10.0/10Revenue up 316.8% over 1 year.
Revenue (trailing 12 months)
123M CNY
Revenue growth (1y)
316.80%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
1.9Md CNY
Financial strength
4.4/10Cash covers 25186.2% of the debt, net debt/EBITDA 4.8x.
Net debt / EBITDA
4.8x
Stretched
Gearing (net debt / equity)
-136.79%
Net cash
Cash
1.1Md CNY
Cash / market cap
57.89%
Very solid
Cash / total debt
25186.24%
Net cash
Interest coverage
-3.5x
Stretched
Net debt
-1.1Md CNY
Equity
821M CNY
Closed daily candles, 6 months
Last close on November 20, 2026: 8.10 HKD
- MM209.08
- MM5011.45
- RSI 1437.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
50-day average slope, 1 month
-14.53%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
6.21 % per day
Volatility change
-13.07%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | — | -0.57 (1) | 282 (1) | -120 (1) | — |
| 2027 | — | -0.10 (1) | 463 (1) | -36 (1) | — |
Amounts in millions of CNY, EPS in CNY per share. In brackets, the number of analysts. Consensus as of November 17, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 316.8 % | -60.5 % | 4.8x | -5.2 % | — | ||
| 5 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 6 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 8 | GLSI | 1.5 | N/A | 283M USD | Not meaningful (loss) | — | — | -10656.2 % | 0.3x | -4.5 % | 134.2 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
